Search scope:
排序: Display mode:
Hydroxyl radical-involved cancer therapy via Fenton reactions
Frontiers of Chemical Science and Engineering 2022, Volume 16, Issue 3, Pages 345-363 doi: 10.1007/s11705-021-2077-3
Keywords: hydroxyl radical Fenton catalyst hydrogen peroxide cancer therapy
Progress and challenges in RET-targeted cancer therapy
Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y
Keywords: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
Frontiers of Medicine 2021, Volume 15, Issue 2, Pages 221-231 doi: 10.1007/s11684-020-0812-7
Keywords: mTOR cancer therapy resistance GSK3 protein degradation E3 ubiquitin ligase PD-L1
Bioorthogonal chemistry based on-demand drug delivery system in cancer therapy
Frontiers of Chemical Science and Engineering 2023, Volume 17, Issue 4, Pages 483-489 doi: 10.1007/s11705-022-2227-2
Keywords: bioorthogonal reaction cancer therapy metabolic glycoengineering bioorthogonal catalytic patch
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
Yingyan Yu
Frontiers of Medicine 2018, Volume 12, Issue 2, Pages 229-235 doi: 10.1007/s11684-017-0581-0
On May 23, 2017, the US Food and Drug Administration (FDA) approved a treatment for cancer patientstreatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-cell lung cancer, recurrent or metastatic head and neck cancer, refractory Hodgkin lymphoma, and urothelial carcinomaTaking gastric cancer as an example, its molecular classification is built on genome abnormalities, butSubsequently, by using their findings, oncologists will carry out targeted therapy based on molecular
Keywords: molecular classification precision medicine pembrolizumab PD-1/PD-L1 MSI-H
Particle therapy for cancers: a new weapon in radiation therapy
Guo-Liang Jiang
Frontiers of Medicine 2012, Volume 6, Issue 2, Pages 165-172 doi: 10.1007/s11684-012-0196-4
Keywords: radiation therapy particle therapy proton carbon cancer
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
Frontiers of Medicine 2010, Volume 4, Issue 3, Pages 290-293 doi: 10.1007/s11684-010-0093-7
Keywords: breast cancer postmenopausal hormone therapy unopposed estrogen therapy combined estrogen-progestin therapy
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
Frontiers of Medicine 2009, Volume 3, Issue 3, Pages 245-255 doi: 10.1007/s11684-009-0044-3
Keywords: lung cancer carcinoma non-small cell lung cancer molecular markers targeted therapy
Iron oxide nanoparticle-based theranostics for cancer imaging and therapy
Xiaoqing REN,Hongwei CHEN,Victor YANG,Duxin SUN
Frontiers of Chemical Science and Engineering 2014, Volume 8, Issue 3, Pages 253-264 doi: 10.1007/s11705-014-1425-y
Keywords: theranostics iron oxide nanoparticles MRI drug delivery photothermal therapy photodynamic therapy
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
Frontiers of Medicine 2022, Volume 16, Issue 5, Pages 766-772 doi: 10.1007/s11684-021-0916-8
Keywords: anlotinib chemotherapy short-term relapsed small-cell lung cancer
Frontiers of Medicine doi: 10.1007/s11684-023-1050-6
Keywords: pancreatic cancer cancer screening single cell molecular alterations precancerous lesion therapy
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
Frontiers of Medicine 2021, Volume 15, Issue 1, Pages 1-10 doi: 10.1007/s11684-020-0741-5
Keywords: triple-negative breast cancer immunotherapy targeted therapy
Complex interplay between tumor microenvironment and cancer therapy
Minhong Shen, Yibin Kang
Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 426-439 doi: 10.1007/s11684-018-0663-7
Keywords: tumor microenvironment therapy response treatment resistance
Emerging immunological strategies: recent advances and future directions
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x
Keywords: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy
Frontiers of Medicine 2022, Volume 16, Issue 3, Pages 307-321 doi: 10.1007/s11684-022-0927-0
Keywords: tumor immunotherapy immune checkpoint inhibitor antibiotics gut microbiota drug–drug interaction
Title Author Date Type Operation
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Shi-Yong Sun
Journal Article
Molecular classification and precision therapy of cancer: immune checkpoint inhibitors
Yingyan Yu
Journal Article
How to judge the association of postmenopausal hormone therapy and the risk of breast cancer
Ling XU
Journal Article
Molecular markers and pathogenically targeted therapy in non-small cell lung cancer
Bo PENG BA , Jinnong ZHANG MD , Jamile S. WOODS MD , Wei PENG MD, PhD
Journal Article
Iron oxide nanoparticle-based theranostics for cancer imaging and therapy
Xiaoqing REN,Hongwei CHEN,Victor YANG,Duxin SUN
Journal Article
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup
Journal Article
Improving the prognosis of pancreatic cancer: insights from epidemiology, genomic alterations, and therapeutic
Journal Article
Progress in systemic therapy for triple-negative breast cancer
Hongnan Mo, Binghe Xu
Journal Article
Complex interplay between tumor microenvironment and cancer therapy
Minhong Shen, Yibin Kang
Journal Article